Finding promising penny stocks with major potential is the key to making BANK with trading! Yatsen Holding Limited (NYSE: YSG), Clovis Oncology, Inc. (NASDAQ: CLVS) and Coupang, Inc. (NYSE: CPNG) are among the top penny stocks to buy RIGHT NOW! In this article, we talk about their latest catalysts, future plans – and all the reasons why we think these three stocks could keep running.


Since May 24th, Yatsen Holding Limited (NYSE: YSG) has been rebounding gracefully. Despite dropping 90% over the last year, the recent 120% increase has been catching investors’ attention and showing promising signs of growth long term. Let’s dive deeper into the company’s latest catalysts – as well as its long-term plans – and how they’ve been the main driver of this recent growth.

On June 2nd, the leading Chinese beauty company announced the publication of its first Environmental, Social, and Governance (ESG) report – which underscores the company’s strategic ESG initiatives as a long-term, sustainable business. This, along with the company’s ESG achievements for the 2021 fiscal year, has helped prompt the rebound that we see.

This campaign clearly had a positive impact. On June 22nd, the company had its earnings call  – which demonstrated robust financial results for its skincare brands. Net revenues saw a 68.5% YOY increase to RMB 183 million in Q1. YSG has assured investors that it is laser-focused on maintaining this growth in its other business segments through many planned campaigns in the coming months.

Looking at YSG’s chart, investors seem bullish that the company’s efforts could potentially push it higher to trade at $3 in the coming days. Wanna stay in the loop? Get the best alerts here!

After seeing a 120% rebound over the past month, YSG is now trading at its resistance of $1.81 with support at .97 and another at .71. Accumulation is on an uptrend while the RSI is at 78 and is also increasing. Similarly, the MACD is bullish to the upside.

These indicators clearly show investors’ bullish sentiment – supported by strong financials and solid long-term expansion plans. Given that the stock is currently trading at its resistance, bullish investors could wait for a pullback to its support at .97 and for the RSI to cool off before finding a good entry point on this promising stock.


As a biopharma company known for acquiring, developing, and commercializing innovative anti-cancer agents in several markets, Clovis Oncology, Inc. (NASDAQ: CLVS) has been making headlines this week. By targeting different developmental programs, the company recently announced Phase 1 data from ongoing clinical studies of its targeted radiotherapy candidate FAP-2286. Overall, the results of the test demonstrated a manageable safety profile and encouraging evidence of activity.

Jonathan McConathy – Associate Professor and Director of the Division of Molecular Imaging and Therapeutics – believes “these initial results demonstrate that FAP is a promising theranostic target with expression across many types of solid tumors”. With this in mind, as the company continues developing its studies, CLVS could see lucrative gains in the near future.

Highlighting the company’s future plans, Patrick J. Mahaff – President & CEO – shared that:

“We look forward to presenting additional clinical data from the LuMIERE study at another nuclear medical meeting and initiating Phase 2 expansion cohorts in multiple tumor types later in 2022.”

Trading at its resistance of $2.87, CLVS shows support at 1.58 and .81. Accumulation is on a steep upward trend and MACD is bullish to the upside and shows no signs of an incoming crossover. On a similar trend, RSI is at 82 and continues to trend upwards – indicating the stock is extremely overbought.


On July 1st, Coupang, Inc. (NYSE: CPNG) shares rallied 12% higher – marking itself on many investors’ watchlists. The South Korean e-commerce company now continues to climb up the list of top gainers this week despite the challenges it faces given the evident slowdown in consumer spending due to higher prices.

To overcome this challenge, Coupang has been focused on increasing its profitability through different growth initiatives. The company is already seeing major change as evident by its Q1 2022 financials. With $5.1 billion in total net revenue, CPNG saw a 22% YOY revenue growth along with an improved net loss of $196 million compared to $209 million in the previous quarter.

Gaurav Anand, CFO of Coupang is proud of the company’s growth and continues to assure investors of its growth efforts saying:

“We also recorded the highest gross profit and gross profit margin in the Company’s history, which in turn helped our Product Commerce segment to achieve profitability in Q1. We expect our focus on customer-driven innovations as well as operational excellence to continue to bear fruit in the quarters and years ahead.”

Following its recent run-up, CPNG is now trading at $15.02. It shows support at 12.60 and 11.52. Accumulation has been climbing up and continues to trend upwards. MACD is on a recent bullish crossover while RSI is at 75 – indicating the stock is currently overbought.


Technical analysis of these three promising stocks – YSG, CLVS and CPNG – reveals investors’ bullish sentiment and belief that the companies have major potential. Given that three stocks are now trading at their resistance, investors can wait for a pullback and for the RSI to cool off before securing a position. Get the best alerts here & stay ahead of the game always!!

As always, good luck to all (except the shorts)!

Disclosure: We have no business relationship with any company whose stock is mentioned in this video. Viral Stocks is not an investment advisor and this video does not provide investment advice. Always do your own research, make your own investment decisions, or consult with your nearest financial advisor. This video is not a solicitation or recommendation to buy, sell, or hold securities. This video is our opinion and is meant for informational and educational purposes only and does not provide investment advice. Past performance is not indicative of future performance.

Leave a Reply

Your email address will not be published. Required fields are marked *